Evidence map›Paper›PMID 25077117›Full record

ArticleCMAJ open2013

Trends in use and cost of initial cancer treatment in Ontario: a population-based descriptive study.

Claire de Oliveira, Karen E Bremner, Reka Pataky, Nadia Gunraj, Mahbubul Haq, Kelvin Chan, Winson Y Cheung, Jeffrey S Hoch, Stuart Peacock, Murray D Krahn

Abstract read
In one paragraph

Article in CMAJ open, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Claire de OliveiraCentre for Addiction and Mental Health, Toronto Health Economics and Technology Assessment Collaborative, Toronto, Ont.
Karen E BremnerUniversity Health Network, Toronto Health Economics and Technology Assessment Collaborative, Toronto, Ont.
Reka PatakyCanadian Centre for Applied Research in Cancer Control, British Columbia Cancer Agency, Vancouver, BC.
Nadia GunrajInstitute for Clinical Evaluative Sciences, Sunnybrook Health Sciences Centre, Toronto, Ont.
Mahbubul HaqInstitute for Clinical Evaluative Sciences, Sunnybrook Health Sciences Centre, Toronto, Ont.
Kelvin ChanDepartment of Medicine, University of Toronto, Sunnybrook Health Sciences Centre and Princess Margaret Hospital, Toronto, Ont.
Winson Y CheungBritish Columbia Cancer Agency, University of British Columbia, Vancouver, BC.
Jeffrey S HochCanadian Centre for Applied Research in Cancer Control, St. Michael's Hospital, Cancer Care Ontario, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ont.
Stuart PeacockCanadian Centre for Applied Research in Cancer Control, British Columbia Cancer Agency, School of Population and Public Health, University of British Columbia, Vancouver, BC.
Murray D KrahnToronto Health Economics and Technology Assessment Collaborative, Department of Medicine and Faculty of Pharmacy, University of Toronto, University Health Network, Toronto, Ont.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCancer incidence and treatment-related costs are rising in Canada. We estimated health care use and costs in the first year after diagnosis for patients with 7 common types of cancer in Ontario to examine temporal trends in patterns of care and costs.

methodsWe selected patients aged 19-44 years who had received a diagnosis of melanoma, breast cancer (female only), testicular cancer or thyroid cancer, in addition to patients aged 45 years and older who had received a diagnosis of breast (female only), prostate, lung or colorectal cancer, between 1997 and 2007. Patients were identified from the Ontario Cancer Registry. Using linked administrative databases, we determined use and costs of chemotherapy, radiotherapy, cancer-related surgery, other admissions to hospital and home care. We adjusted all costs to 2009 Canadian dollars.

resultsWe identified 20 821 patients aged 19-44 years and 178 797 patients aged 45 years and older. The greatest increases in costs during the study period were for melanoma, breast cancer, colorectal cancer, lung cancer and prostate cancer (p < 0.05). For prostate and lung cancers, mean costs increased 50% (from $11 490 and $22 037 to $15 170 and $34 473, respectively). Mean costs doubled for breast (from $15 460 and $12 909 to $35 977 and $29 362 for younger and older patients, respectively) and colorectal cancers (from $24 769 to $43 964), and nearly tripled for melanoma (from $3581 to $8934). Costs related to hospital admissions accounted for the largest portion of total costs. The use of chemotherapy, radiotherapy and home care generally increased for all cancers.

interpretationThe significant increase in mean costs of initial cancer treatment among the patients included in this study was primarily due to more patients receiving adjuvant therapy and home care, and to the increasing expenditures for these services and cancer-related surgeries. Understanding trends in health care use and costs can help policy-makers to take the necessary measures to achieve a more accountable, high-performing health care system.

Identifiers

PMID25077117
PMCPMC3986020

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.